Article
Oncology
Lindsey Gallagher, Jerry Xiao, Jessica Hsueh, Sarthak Shah, Malika Danner, Alan Zwart, Marilyn Ayoob, Thomas Yung, Tiffany Simpson, Mark Fallick, Deepak Kumar, Paul Leger, Nancy A. Dawson, Simeng Suy, Sean P. Collins
Summary: This study aimed to evaluate early testosterone suppression and PSA response following relugolix and SBRT for intermediate to high-risk prostate cancer. The results showed that relugolix combined with SBRT achieved high levels of testosterone suppression and low early PSA nadirs.
FRONTIERS IN ONCOLOGY
(2023)
Review
Gastroenterology & Hepatology
Xing Chen, Jinpeng Du, Jiwei Huang, Yong Zeng, Kefei Yuan
Summary: Intrahepatic cholangiocarcinoma (ICC) is a common type of primary liver cancer with increasing incidence. Due to the lack of specific manifestations and tools for early diagnosis, most patients are diagnosed at an advanced stage. Neoadjuvant and adjuvant therapies are necessary to improve the outcomes, but lag behind compared to other malignancies. Recent advances in neoadjuvant and adjuvant strategies for ICC are evaluated in this review.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2022)
Article
Oncology
Rogier Baak, Francois E. J. A. Willemssen, Yvette van Norden, Ferry A. L. M. Eskens, Maaike T. W. Milder, Ben J. M. Heijmen, Bas Groot Koerkamp, Dave Sprengers, Lydi M. J. W. van Driel, Heinz-Josef Klumpen, Wilhelm den Toom, Merel S. Koedijk, Jan N. M. IJzermans, Alejandra Mendez Romero
Summary: This study examined the feasibility and safety of adding SBRT treatment in patients with unresectable perihilar cholangiocarcinoma, showing promising results in terms of local control and overall survival. However, further evaluation in a larger patient population is recommended due to the small sample size in this study.
Article
Pathology
Gwyneth S. T. Soon, Saba Yasir, Tsung-Teh Wu, Christopher Welle, Sudhakar K. Venkatesh, Michael S. Torbenson, Zongming Eric Chen
Summary: Newer radiotherapy techniques, such as stereotactic body radiation, are increasingly used in the treatment of cholangiocarcinomas, particularly as a bridge to liver transplantation. However, these high-dose therapies result in tissue injury in the peritumoral liver tissue. This retrospective study characterized the morphologic changes in the liver after stereotactic body radiation and found that the changes in the radiated areas were more extensive than in the background liver.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2023)
Review
Oncology
Xiao-xue Zhang, Hong-bin Ma, Tie-hua Li, Bin Huang, Ning-yang Jia, Yan Meng
Summary: This study evaluated the factors affecting the local control rate after SBRT treatment and predicted the factors affecting survival rates. The 3-year actual survival rates after treatment were reported, and the influencing factors of the 3-year survival rate were identified.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Article
Oncology
Casey Moore, Ching-Cheng Hsu, Wei-Min Chen, Benjamin P. C. Chen, Chuanhui Han, Michael Story, Todd Aguilera, Laurentiu M. Pop, Raquibul Hannan, Yang-Xin Fu, Debabrata Saha, Robert Timmerman
Summary: Combining radiation with immunotherapy can harness immune-stimulatory effects for better tumor treatment outcomes. Factors such as immunotherapy and radiation dose sequencing, as well as radiation fraction spacing, impact the response to combination therapy. Personalized PULSAR-style radiation dosing shows better tumor control in this model, emphasizing the importance of preclinical investigation in designing clinical trials for combination therapy.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Seo Hee Choi, Chai Hong Rim, In-Soo Shin, Won Sup Yoon, Woong Sub Koom, Jinsil Seong
Summary: The study shows that adjuvant radiotherapy can improve overall survival in patients with extrahepatic cholangiocarcinoma, and further confirm this result in studies with reliable comparability.
Article
Oncology
Robert Olson, Will Jiang, Mitchell Liu, Alanah Bergman, Devin Schellenberg, Benjamin Mou, Abraham Alexander, Hannah Carolan, Fred Hsu, Stacy Miller, Siavash Atrchian, Elisa Chan, Clement Ho, Islam Mohamed, Angela Lin, Tanya Berrang, Andrew Bang, Nick Chng, Quinn Matthews, Sarah Baker, Vicky Huang, Ante Mestrovic, Derek Hyde, Chad Lund, Howard Pai, Boris Valev, Shilo Lefresene, Scott Tyldesley
Summary: This study confirms that the incidence of high-grade toxic effects in the large cohort of patients receiving SABR for oligometastases is less than 5%. The lower rates of toxic effects compared to previous studies may support further enrollment in randomized phase 3 clinical trials.
Article
Radiology, Nuclear Medicine & Medical Imaging
Giuditta Chiloiro, Luca Boldrini, Angela Romano, Lorenzo Placidi, Huong Elena Tran, Matteo Nardini, Mariangela Massaccesi, Francesco Cellini, Luca Indovina, Maria Antonietta Gambacorta
Summary: This retrospective study evaluated the feasibility and clinical benefit of MRgSBRT in patients with oligometastatic disease. The results showed that MRgSBRT was well tolerated by patients and had a satisfying clinical outcome.
Article
Clinical Neurology
Zach Pennington, Sutipat Pairojboriboon, Xuguang Chen, Amanda Sacino, Aladine A. Elsamadicy, Rafael de la Garza Ramos, Jaimin Patel, Benjamin D. Elder, Lawrence R. Kleinberg, Daniel M. Sciubba, Kristin J. Redmond, Sheng-fu Larry Lo
Summary: This study aimed to examine the effect of anterior column debulking versus epidural disease resection alone on the local control of metastases to the bony spine. The study found that anterior column debulking decreased the odds of local recurrence and improved long-term local control compared to epidural debulking-alone.
Article
Oncology
Salvatore Paiella, Giuseppe Malleo, Nicola Simoni, Renato Micera, Stefania Guariglia, Carlo Cavedon, Giovanni Marchegiani, Alessandro Esposito, Luca Landoni, Luca Casetti, Massimiliano Tuveri, Michele Milella, Erica Secchettin, Gessica Manzini, Chiara Bovo, Matteo De Pastena, Martina Fontana, Roberto Salvia, Renzo Mazzarotto, Claudio Bassi
Summary: The study aims to investigate the efficacy of total neoadjuvant therapy with FOLFIRINOX and hypofractionated SBRT in patients with BRPC, followed by IORT, with the primary endpoint being 3-year survival. The trial plans to recruit 100 patients over 36 months and assess secondary endpoints such as completion of treatment, resection rate, toxicities, and progression-free survival.
Article
Medicine, General & Internal
Annaig Bertho, Morgane Dos Santos, Sarah Braga-Cohen, Valerie Buard, Vincent Paget, Olivier Guipaud, Georges Tarlet, Fabien Milliat, Agnes Francois
Summary: By utilizing three-fraction schedules delivered over a period of 1 week with doses per fraction of 20, 28, 40, and 50 Gy, only 3 x 40 Gy or 3 x 50 Gy generated focal lung fibrosis after 6 months. The study suggests that a fractionation schedule using an arc-therapy-delivered three fractions/1 week regimen with 3 x 3 mm beam requires 40 Gy per fraction for lung fibrosis to develop within 6 months.
FRONTIERS IN MEDICINE
(2021)
Article
Oncology
Henan Zhang, Jacob J. Orme, Feven Abraha, B. J. Stish, Val J. Lowe, Fabrice Lucien, Erik J. Tryggestad, Michael S. Bold, Lance C. Pagliaro, C. Richard Choo, Debra H. Brinkmann, Matthew J. Iott, Brian J. Davis, J. Fernando Quevedo, William S. Harmsen, Brian A. Costello, Geoffrey B. Johnson, Mark A. Nathan, Kenneth R. Olivier, Thomas M. Pisansky, Eugene D. Kwon, Haidong Dong, Sean S. Park
Summary: The study showed that high levels of tumor-reactive T cells and effector memory T cells were associated with better outcomes in oligometastatic CRPC patients treated with SABR. This supports the incorporation of immune-based markers in the design of future randomized trials in this patient population.
CLINICAL CANCER RESEARCH
(2021)
Article
Chemistry, Physical
M. Savanovic, D. Jaros, P. Chauchat, J. N. Foulquier
Summary: The study evaluated absolute dose in lung SBRT between phase- and amplitude-gated modes using in-house developed moving targets. Results showed that the microDiamond detector had the lowest dose discrepancy in phase-gated mode, while the Pinpoint ion chamber had lower discrepancy in amplitude-gated mode, and the Semiflex ion chamber showed the greatest discrepancy.
RADIATION PHYSICS AND CHEMISTRY
(2021)
Review
Oncology
Joanna Jiang, Dayssy Alexandra Diaz, Surya Pratik Nuguru, Arjun Mittra, Ashish Manne
Summary: Liver and biliary tract cancers are aggressive with limited treatment options. Combining high-dose radiation with immunotherapy shows promise for improving efficacy, but more research is needed. The combination of stereotactic body radiation therapy (SBRT) and immune checkpoint inhibitors (ICI) could be explored for advanced primary liver tumors and cholangiocarcinoma. Large-scale trials are necessary to determine the suitable patient population and assess the clinical benefit. Rating: 8/10.